Resposta virológica sustentada para a Hepatite C

Abstract

The hepatitis C virus (HCV) is a serious public health problem worldwide, affecting about 170,000,000 people across the planet, by infecting the individual and becoming chronic the disease triggers various liver problems such as cirrhosis and carcinomas. This RNA of the Flaviviridae family has 6 known genotypes, it is known that in Brazil the most common HCV genotypes are 1,2 and 3. The virus is diagnosed by serological (Anti-HCV) and molecular (HCV- RNA), as well as additional tests for specificity and sensitivity for more accurate detection. There are findings of several cells of the innate and adaptive immune response involved in the attempt to combat the virus, such as Natural Killer (NK) cells, T and B lymphocytes, as well as several other humoral mediations. The drugs were able to increase the chances of cure, known as Sustained Virological Response (SVR), between 40% and 90%, when associated with triple therapy, such drugs are characterized as inhibitors of first generation proteases (Telaprevir and Boceprevir) (Simeprevir) inhibitors, polymerase inhibitors (Sofosbuvir) and inhibitors of the virus NS5A protein (Daclatasvir), along with medications already used previously to triple therapy are the use of Ribavirin and Interferon-pegged, also known as Dual therapy, when not inserted the use of inhibitors. In the analysis of 5 study articles, it was observed that despite the side effects, large percentages of individuals achieved SVR, in shorter periods of treatment, triple therapies are capable of promoting cure, whether they are done with any type of inhibitors.